Making AI better.

Helping patients afford healthcare.

- Thought partner for clients ranging from cutting-edge biotech companies to top 10 large pharmaceutical companies- Core expertise in big data / machine learning / AI application, oncology portfolio strategy, and commercialization excellenceSelect projects: - Spearheaded development and alignment for oncology portfolio strategy of multi-billion dollar biotech company with cross-functional executives- Creation of commercialization strategy for COVID oral antiviral, including big-data analysis of insurance claims- Developing actionable physician / patient segmentations for commercialization of oncology drugs using machine learning / artificial intelligence

- Over 500 hours of cutting-edge translational research for embryonic gene therapy (research goal of saving children’s lives by preventing genetic disease before birth)- Designed initial clinical trials and presented business plans to investors at Life Sciences Future Conference- Published in Nature Biotechnology: https://www.nature.com/articles/s41467-021-24443-8

-Researcher at the Novartis-Penn Center for Advanced Cellular Therapies, which developed the first FDA-approved CAR-T Therapy (Kymriah, 2017)-Led development of machine learning and artificial intelligence models to improve predict CAR-T manufacturing success rates

- Startup to leverage artificial intelligence to improve the drug development process- Developed a machine learning model to predict drug pharmacokinetics / pharmacodynamics in clinical trials

-Over 1,000 hours of research conducting in vivo and in vitro experiments to study hematological disorders and cancers (t-AML and type 1 diabetes)-Co-authorship of paper published in Proceedings of National Academy of Sciences (PNAS): http://www.pnas.org/content/113/3/650-Selected to represent over 100 student researchers at 2014 California Institute of Regenerative Medicine (CIRM) conference, earned CIRM Creativity Award